SciELO - Scientific Electronic Library Online

vol.60 número9Atrapamiento peneano por anillos metálicosTumor vesical infiltrante 18 meses después de nefrectomía radical laparoscópica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Archivos Españoles de Urología (Ed. impresa)

versión impresa ISSN 0004-0614

Arch. Esp. Urol. vol.60 no.9  nov. 2007




Dear colleague,

Many thanks to Prof. Dr. Ramon Abascal Garcia for his clear statement to fluorescence diagnosis of bladder cancer by 5- amino-levolinic acid (ALA). This method was developed on the Dept of Urology and the Laser Research Center of University of Munich - Grosshadern in 1990 under my supervision.

A supposed low specifity led to refusal of this method although sensitivity was about 98 %. Especially flat lesions and carcinomata in situ can be recognized by ALA - induced fluorescence: this is an important step in diagnosis as well as treatment of bladder cancer.

The false positive fluorescence after ALA-instillation is mainly evoked by inflammation of bladder mucosa. As we could see by spectralanalysis, this is a fluorescence from a other kind of porphyrine, however. Well trained endoscopists can also confirm that the fluorescences differ. But in our opinion, the different red - fluorescences are not so important because for confirmation - cancer or not- you need a biopsy in any case.

The story with ALA and light (xenon- or laserlight) is not yet finished: there are new fields e.g. in treatment of solid tumors and metastases after systemic ALA-application. The first results in treatment of brain - and prostate cancers are interesting.


Univ. Prof. Dr. Alfons Hofstetter
Director of Dept. of Urology and Life-Research Center
University of Munich
Munich (Germany).

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons